Loading…
Medicaid Drug Decisions Transparency Act
Legislative Progress
Introduced
December 18, 2018
Latest Action
December 18, 2018
Primary Sponsor
Cory A. BookerDemocratic(NJ)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Medicaid Drug Decisions Transparency Act This bill expands Medicaid and Medicare reporting requirements related to the transparency of physician ownership or investment interests to include pharmacists and individuals with authority over Medicaid formularies, and also increases civil penalties for violations.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2018 · fourth_quarter · Health Issues
implementation of health care reform generally pertaining to pediatric health care and autism services Medicaid program reforms, including hospital outpatient department regulations S.3770 (Medicaid Drug Decisions Transparency Act), all provisions Section 340B Drug Pricing Program, including H.R. 4710 (340B PAUSE Act), All provisions, and H.R. 5598 (340B Optimization Act), all provisions and H.R. 6240 (drug Discount accountability act), all provisions Sickle Cell Disease Research funding generally Drug pricing reforms generally Department of Justice implementation of grant program for missing individuals with autism and developmental disabilities Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 2410 (Sickle Cell Disease research, Surveillance, prevention and treatment act of 2017), all provisions S. 2465 (Sickle cell disease and other heritable blood disorders research, surveillance, Prevention and treatment act of 2018), all provisions H.R. 3325 (ACE kids Act), all provisions S. 428 (Ace Kids Act of 2017), all provisions H.R. 1676 (Palliative Care and Hospice Education and Training Act), all provisions Organ Transplant policy generally, including transplant distribution methodology H.R. 7217 (Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act - IMPROVE act), Title I, regarding coordinated care
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $132,091 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Medicaid program reforms, including possible regulations involving hospital outpatient departments Implementation of health care reform Section 340B Drug Pricing Program Healthcare disparities issues generally Drug pricing reforms generally H.R. 6524 and S. 2415 (Accelerating Kids' Access to Care Act), all provisions H.R. 3325 (ACE Kids Act), all provisions S. 428 (ACE Kids Act of 2017), all provisions Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 7217 (Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act - IMPROVE Act), Title I, regarding coordinated care S. 3770 (Medicaid Drug Decisions Transparency Act), all provisions Poison Control Center funding programs generally Implementation of Public Law 115-91 (National Defense Authorization Act for Fiscal Year 2018), Section 708, regarding TRICARE policies for patient referrals regarding pregnant women Medical interpreters and patient language access issues generally
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Implementation of health care reform generally pertaining to pediatric health care and autism services Medicaid program reforms, including hospital outpatient department regulations S. 3770 (Medicaid Drug Decisions Transparency Act), all provisions Section 340B Drug Pricing Program, including H.R. 4710 (340B PAUSE Act), all provisions, H.R. 5598 (340B Optimization Act), all provisions, and H.R. 6240 (Drug Discount Accountability Act), all provisions Sickle cell disease research funding generally Drug pricing reforms generally Department of Justice implementation of grant program for missing individuals with autism and developmental disabilities Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 2410 (Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017), all provisions S. 2465 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018), all provisions H.R. 3325 (ACE Kids Act), all provisions S. 428 (ACE Kids Act of 2017), all provisions H.R. 1676 (Palliative Care and Hospice Education and Training Act), all provisions Organ transplant policy generally, including liver transplant distribution methodology H.R. 7217 (Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act - IMPROVE Act), Title I, regarding coordinated care
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Medicaid program reforms, including possible regulations involving hospital outpatient departments Implementation of health care reform Section 340B Drug Pricing program Healthcare disparities issues generally Drug pricing reforms generally H.R. 6524 and S. 2415 (Accelerating Kids' Access to Care Act), all provisions H.R. 3325 (ACE Kids Act), all provisions S. 428 (ACE Kids Act of 2017), all provisions Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 7217 (Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act - IMPROVE Act), Title I, regarding coordinated care S. 3770 (Medicaid Drug Decisions Transparency Act), all provisions Poison Control Center funding programs generally Implementation of Public Law 115-91 (National Defense Authorization Act for Fiscal Year 2018), Section 708, regarding TRICARE policies for patient referrals involving pregnant women
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Medicare/Medicaid
H.R.6505 - Medicare Negotiation and Competitive Licensing Act - require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program Oral health -Medicare dental benefit; Medicare coverage of medically necessary oral health care S.3770 - Medicaid Drug Decisions Transparency Act - expand the scope of transparency reporting requirements related to the ownership or investment interests of health care providers and others, and to increase the penalties associated with violating such requirements H.R. 7217 - IMPROVE Act - extend the Medicaid HCBS spousal impoverishment protections through March and reauthorize the Money Follows the Person Program with 3 months of funding H.R. 6 - Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act - Section 5021, 5022 - H.R. 3192, the CHIP Mental Health Parity Act; Section 5031, 5032 - H.R. 4005, the Medicaid Reentry Act; S.3462 - Improving Coverage for Substance Use Disorder Recovery Expansion Act - provide States with the option to provide medical assistance for substance use disorder treatment services to individuals; modification of IMD exclusion H.R. 5797 - Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act - partial removal of IMD exclusion Legislation to expand Medicare coverage Legislation around discounts the pharmaceutical industry must provide for drugs purchased in the Medicare Part D donut hole
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE